BIND Therapeutics: Cowen and Company Healthcare Conference (BIND Therapeutics) - Mar 5, 2015 - “BIND-014 mCRPC Topline Data”; “Patients with metastatic castrate-resistant prostate with no prior chemotherapy treated BIND-014 60 mg/m2 administered every 21 days (n=42)”; “Primary endpoint: radiographic progression-free survival (rPFS)”; “Substantial clinical activity in a less responsive patient population than historical controls: 31/42 (74%) had prior abiraterone and/or enzalutamide vs. 0% in TAX-327, Median rPFS of 8.1 months vs. 6-8 months in earlier stage historical controls, 60% of patients enrolled attained a rPFS of 6 months or greater, Reduced incidence of typical docetaxel-related hematologic and non-hematologic toxicities, Internally consistent activity in secondary endpoint outcomes, including PSA responses and reductions in circulating tumor cell counts, Overall survival immature. As of December 15, 2014, two patients continue on treatment and 24 patients continue to be followed for overall...
P2 data • Oncology • Prostate Cancer
|